1832 Asset Management’s BeOne Medicines ONC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
– Sell
-80,000
Closed -$27.3M – 778
2025
Q3
$27.3M Buy
+80,000
New +$24.3M 0.02% 243
2023
Q1
– Sell
-800
Closed -$176K – 992
2022
Q4
$176K Buy
800
+742
+1,279% +$136K ﹤0.01% 699
2022
Q3
$8K Buy
+58
New +$10K ﹤0.01% 813
2021
Q4
– Sell
-30,800
Closed -$11.2M – 880
2021
Q3
$11.2M Sell
30,800
-2,000
-6% -$654K 0.02% 319
2021
Q2
$11.7M Buy
32,800
+2,500
+8% +$828K 0.02% 293
2021
Q1
$10.1M Buy
30,300
+4,000
+15% +$1.32M 0.02% 290
2020
Q4
$6.73M Buy
+26,300
New +$7.24M 0.02% 328

Other funds holding ONC

1832 Asset Management's ONC Position: Q4 2025 in Review

1832 Asset Management sold out of BeOne Medicines (ONC) in Q4 2025, closing a stake of 80,000 shares — an estimated $27.3M sold.

1832 Asset Management first reported a position in ONC in Q4 2020 and held it in 7 quarters. The position peaked at $27.3M in Q3 2025. 288 funds tracked by Wall St. Rank hold ONC as of Q4 2025.

  • 1832 Asset Management reported no remaining BeOne Medicines position as of Q4 2025 after selling out during the quarter.
  • 1832 Asset Management sold 80,000 BeOne Medicines shares in Q4 2025, an estimated $27.3M.
  • 1832 Asset Management first reported a position in BeOne Medicines in Q4 2020 and held it in 7 quarters.
  • 1832 Asset Management's BeOne Medicines position peaked at $27.3M in Q3 2025.
  • 288 funds tracked by Wall St. Rank held BeOne Medicines as of Q4 2025.

Based on 1832 Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.